{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:02:39Z","timestamp":1787029359209,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T00:00:00Z","timestamp":1728864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"contest of the multiregional active pharmacovigilance Italian Medicines Agency (AIFA)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: The treatment of psoriasis has made considerable progress with biologicals, including tumor necrosis factor inhibitors, and recently, monoclonal antibodies inhibiting directly interleukin (IL) 17, IL-23, or both IL-12\/23. Newer biologicals are directed to the interleukin pathway and appear to improve complete or near-complete clearance. The newer biologicals have also been shown to have an excellent safety profile. However, despite experience with patients having confirmed the results obtained in clinical trials, there are still few data on using the newer biologicals. Methods: The present active study aimed to prospectively evaluate safety profiles and persistence of some biologicals in a multicenter pharmacovigilance study, that enrolled 733 patients treated with a biologic drug in five Calabrian hospital units. Informative and treatment persistence evaluations with predictors for suspension and occurrence of adverse events (AEs) were executed. In particular, reasons for treatment discontinuation in our program take account of primary\/secondary failure or development of an AE. Results: AEs occurred in 187\/733 patients and serious AEs (SAEs) were identified in 5\/733 patients. An number of 182\/733 patients showed a primary\/secondary inefficacy. The AEs and SAEs were described with adalimumab, infliximab, and etanercept but not with abatacept, brodalumab, tildrakizumab, golinumab, ixekizumab, guselkumab, risankizumab, secukinumab, and ustekinumab. Conclusions: Our analysis, although limited by a small sample size and a short-term follow-up period, offers suitable data on commonly used biological agents and their safety, interruption rate, and the attendance of SAEs. Real-world studies should be carried out to evaluate other safety interests.<\/jats:p>","DOI":"10.3390\/pharmaceutics16101329","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:44:31Z","timestamp":1728909871000},"page":"1329","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Prescribing Pattern and Safety Profile of Biological Agents for Psoriasis in Real-World Practice: A Four-Year Calabrian Pharmacovigilance Analysis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3596-0090","authenticated-orcid":false,"given":"Caterina","family":"De Sarro","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"},{"name":"System and Applied Pharmacology@University Magna Grecia, (FAS@UMG) Research Center, Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bosco","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"},{"name":"System and Applied Pharmacology@University Magna Grecia, (FAS@UMG) Research Center, Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Gagliardi","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Guarnieri","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0401-4027","authenticated-orcid":false,"given":"Stefano","family":"Ruga","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Fabiano","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Costantino","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0061-1608","authenticated-orcid":false,"given":"Antonio","family":"Leo","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"},{"name":"System and Applied Pharmacology@University Magna Grecia, (FAS@UMG) Research Center, Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Palleria","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Verduci","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-5259","authenticated-orcid":false,"given":"Vincenzo","family":"Rania","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ashour","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-7902","authenticated-orcid":false,"given":"Luca","family":"Gallelli","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"},{"name":"System and Applied Pharmacology@University Magna Grecia, (FAS@UMG) Research Center, Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6746-6751","authenticated-orcid":false,"given":"Rita","family":"Citraro","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"},{"name":"System and Applied Pharmacology@University Magna Grecia, (FAS@UMG) Research Center, Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7629-6579","authenticated-orcid":false,"given":"Giovambattista De","family":"Sarro","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"},{"name":"System and Applied Pharmacology@University Magna Grecia, (FAS@UMG) Research Center, Science of Health Department, School of Medicine, Magna Graecia University of Catanzaro, 88100 Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Drakos, A., Torres, T., and Vender, R. (2024). Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010111"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.det.2014.09.002","article-title":"The immunopathogenesis of psoriasis","volume":"33","author":"Kim","year":"2015","journal-title":"Dermatol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/jdv.15177","article-title":"Position statement for the management of comorbidities in psoriasis","volume":"32","author":"Dauden","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/bjd.21047","article-title":"Systematic review and critical appraisal of psoriasis clinical practice guidelines: A Global Guidelines in Dermatology Mapping Project (GUIDEMAP)","volume":"187","author":"Yen","year":"2022","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archdermatol.2011.1410","article-title":"Consensus guidelines for the management of plaque psoriasis","volume":"148","author":"Hsu","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: A systematic literature review and network meta-analysis","volume":"6","author":"Perry","year":"2020","journal-title":"RMD Open"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s40264-014-0224-1","article-title":"Safety Profile of Biological Medicines as Compared with Non-Biologicals: An Analysis of the Italian Spontaneous Reporting System Database","volume":"37","author":"Cutroneo","year":"2014","journal-title":"Drug Saf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1080\/14740338.2017.1316486","article-title":"Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011\u20132014: Impact of a regional pharmacovigilance project in light of the new European Legislation","volume":"16","author":"Leporini","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Palleria, C., Iannone, L., Leporini, C., Citraro, R., Manti, A., Caminiti, M., Gigliotti, P., Grembiale, R.D., L\u2019Andolina, M., and Muccari, G. (2018). Implementing a simple pharmacovigilance program to improve reporting of adverse events associated with biologic therapy in rheumatology: Preliminary results from the Calabria Biologics Pharmacovigilance Program (CBPP). PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205134"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3904\/kjim.2012.27.4.443","article-title":"A Comparison of Active Surveillance Programs Including a Spontaneous Reporting Model for Phamacovigilance of Adverse Drug Events in a Hospital","volume":"27","author":"Yun","year":"2012","journal-title":"Korean J. Intern. Med."},{"key":"ref_11","first-page":"e423","article-title":"Active pharmacovigilance and healthcare utilization","volume":"18","author":"Haas","year":"2012","journal-title":"Am. J. Manag. Care"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.4103\/0976-500X.120955","article-title":"Limitations and obstacles of the spontaneous adverse drugs reactions reporting: Two \u201cchallenging\u201d case reports","volume":"4","author":"Palleria","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e062306","DOI":"10.1136\/bmjopen-2022-062306","article-title":"Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes","volume":"13","author":"Nash","year":"2023","journal-title":"BMJ Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/bjd.19039","article-title":"British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: A rapid update","volume":"183","author":"Smith","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1080\/03007995.2020.1786681","article-title":"Safety profiles of biologic agents for inflammatory bowel diseases: A prospective pharmacovigilance study in Southern Italy","volume":"36","author":"Roberti","year":"2020","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.5114\/ada.2021.108445","article-title":"Treatments in psoriasis: From standard pharmacotherapy to nanotechnology therapy","volume":"39","author":"Zhu","year":"2022","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_17","first-page":"1249","article-title":"Pharmacovigilance of Biologics in a Multisource Environment","volume":"23","author":"Sagi","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_22","first-page":"1","article-title":"Adverse Reactions to Biologics in Psoriasis","volume":"53","author":"Lockwood","year":"2017","journal-title":"Curr. Probl. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5152\/eurjrheum.2021.20230","article-title":"Influence of anti-TNF-\u03b1 treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study","volume":"9","author":"Akyol","year":"2022","journal-title":"Eur. J. Rheumatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/bjd.12045","article-title":"Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: A retrospective, multicentre study in a clinical setting","volume":"168","author":"Navarro","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/bjd.15866","article-title":"Tumour necrosis factor antagonist-induced lupus: A Critically Appraised Topic","volume":"177","author":"Momen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2016.09.013","article-title":"Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?","volume":"101","author":"Chen","year":"2018","journal-title":"Cytokine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Kalden, J.R., and Schulze-Koops, H. (2017). Immunogenicity and Loss of Response to TNF Inhibitors: Implications for Rheumatoid Arthritis Treatment. Nature Reviews Rheumatology, Nature Publishing Group.","DOI":"10.1038\/nrrheum.2017.187"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lin, P.T., Wang, S.H., and Chi, C.C. (2018). Drug survival of biologics in treating psoriasis: A meta-analysis of real-world evidence. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-34293-y"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/hon.2451","article-title":"FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients","volume":"36","author":"Fracchiolla","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kamata, M., and Yayoi, T. (2020). Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051690"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Megna, M., Balato, A., Caccavale, S., Cacciapuoti, S., Calabrese, G., Di Brizzi, E.V., Di Costanzo, L., Manzo, R., Marino, V., and Puca, R.V. (2024). Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092552"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Fiorillo, G., Ibba, L., Gargiulo, L., Narcisi, A., Costanzo, A., and Valenti, M. (2024). Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study. J. Pers. Med., 14.","DOI":"10.3390\/jpm14020186"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/1346-8138.13409","article-title":"Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: Results of SALSA study","volume":"43","author":"Asahina","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Scavone, C., Sportiello, L., Sullo, M.G., Ferrajolo, C., Ruggiero, R., Sessa, M., Berrino, P.M., di Mauro, G., Berrino, L., and Rossi, F. (2017). Safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in Campania Region (Italy): BIOCam observational study. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00607"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/10\/1329\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:13:16Z","timestamp":1760112796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/10\/1329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":34,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["pharmaceutics16101329"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16101329","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}